ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Pediatric Cardiology

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1628666

Successful Interventional Closure of Patent Ductus Arteriosus in Three Pediatric Cases with Congenital Heart Disease and Severe Pulmonary Hypertension: A Case Series and Literature Review

Provisionally accepted
  • 1Sun Yat-sen Memorial Hospital, Guangzhou, China
  • 2Guangdong Provincial People′s Hospital, guangzhou, China

The final, formatted version of the article will be published soon.

Purpose To report three cases of successful closure of patent ductus arteriosus (PDA) with severe pulmonary hypertension (PH) and explore interventional closure strategies for congenital heart disease (CHD) complicated by severe PH. This study aims to determine whether such patients can undergo and benefit from interventional closure, providing clinical insights for physicians.Methods A retrospective analysis was conducted on three pediatric cases of PDA with severe PH successfully treated via interventional closure at the Department of Pediatric Cardiology, Guangdong Provincial People’s Hospital. Literature related to "patent ductus arteriosus," "severe pulmonary hypertension," "Eisenmenger syndrome," "targeted therapy," and "interventional closure" (in both Chinese and English) was searched in PubMed and the China National Knowledge Infrastructure (CNKI) database up to November 2024. Case characteristics and therapeutic strategies were analyzed in conjunction with the literature.Results All three pediatric patients had CHD combined with severe PH and underwent successful PDA occlusion after administration of at least 3 months of endothelin receptor antagonist or PDE5 inhibitor therapy (targeted therapy). Postoperative targeted therapy was continued, with follow-up until November 30, 2024. No significant elevation in pulmonary artery pressure (PAH) was observed, and exercise tolerance markedly improved in all cases.Conclusion Children with CHD and severe PH may qualify for interventional closure after a period of targeted therapy and could benefit from this procedure. Administering targeted medications before and after closure not only provides opportunities for intervention but also reduces the risk of persistent postoperative PAH.

Keywords: PDA, Severe PH, Eisenmenger syndrome, targeted therapy, Interventional closure

Received: 14 May 2025; Accepted: 24 Jun 2025.

Copyright: © 2025 Liao, Li, Zeng, Zhang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiong-yu Liao, Sun Yat-sen Memorial Hospital, Guangzhou, China
Yumei Xie, Guangdong Provincial People′s Hospital, guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.